Natural and Synthetic Agents Targeting Reactive Carbonyl Species against Metabolic Syndrome.

Abstract

Reactive carbonyl species (RCS) may originate from the oxidation of unsaturated fatty acids and sugar in conditions of pathology. They are known to have high reactivity towards DNA as well as nucleophilic sites of proteins, resulting in cellular dysfunction. It has been considered that various pathological conditions are associated with an increased level of RCS and their reaction products. Thus, regulating the levels of RCS may be associated with the mitigation of various metabolic and neurodegenerative disorders. In order to perform a comprehensive review, various literature databases, including MEDLINE, EMBASE, along with Google Scholar, were utilized to obtain relevant articles. The voluminous review concluded that various synthetic and natural agents are available or in pipeline research that hold tremendous potential to be used as a drug of choice in the therapeutic management of metabolic syndrome, including obesity, dyslipidemia, diabetes, and diabetes-associated complications of atherosclerosis, neuropathy, and nephropathy. From the available data, it may be emphasized that various synthetic agents, such as carnosine and simvastatin, and natural agents, such as polyphenols and terpenoids, can become a drug of choice in the therapeutic management for combating metabolic syndromes that involve RCS in their pathophysiology. Since the RCS are known to regulate the biological processes, future research warrants detailed investigations to decipher the precise mechanism.

• Authors: Tapan Behl, Amit Gupta, Sridevi Chigurupati, Sukhbir Singh, Aayush Sehgal, Vishnu Nayak Badavath, Ahmad Alhowail, Vasudevan Mani, Saurabh Bhatia, Ahmed Al-Harrasi, Simona Bungau
• Journal: Molecules (Basel, Switzerland) (Molecules) Vol. 27 Issue 5 (Feb 27 2022) ISSN: 1420-3049 [Electronic] Switzerland
• PMID: 35268685 (Publication Type: Journal Article, Review)

Topics

• Metabolic Syndrome